Middle East & Africa Injectable Drug Delivery Market

The Middle East & Africa injectable drug delivery market is projected to reach USD 22.54 billion by 2031 from USD 16.46 billion in 2026, growing at a CAGR of 6.5% during the forecast period.

There is an increase in the incidence and prevalence of diseases such as diabetes, cancer, cardiovascular disorders, and infections. This drives the demand for biologics, vaccines, biosimilars, and long-acting injectables across the Middle East & Africa region, thereby boosting growth in the injectable drug delivery market. The growing adoption of prefilled syringes, autoinjectors, pen injectors, microneedle systems, and wearable injectors has been further reinforced through expanding immunization programs, increased shift to home and patient-centric care, and simplicity of self-administration. The increasing adoption of digital health tools and telemedicine will improve remote monitoring and adherence, which are essential for many regions with limited access to health services. New regulations, driven by the expansion of local manufacturing and fill-finish capacities, are also shaping the way collaboration in biopharma is evolving globally, with local companies and government bodies, and further benefiting growth within the Middle East & Africa region.

The prominent injectable drug delivery device manufacturers are BD (US), B. Braun SE (Germany), Terumo Corporation (Japan), Baxter (US), Cardinal Health (US), among others. The injectable drug delivery formulation manufacturers in the Middle East & Africa are Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (US), GSK plc (UK), and Hikma Pharmaceuticals PLC (UK), among others. They have adopted various growth strategies, including organic and inorganic methods, such as product development and partnerships.

To know about the assumptions considered for the study download the pdf brochure

In October 2025, Hikma Pharmaceuticals PLC (UK) signed an exclusive license agreement with Celltrion (South Korea) to extend collaboration work within the Middle East and North Africa region.

In June 2024, Sanofi (France) partnered with Biovac (South Africa) to develop locally manufactured inactivated polio vaccines (IPVs) in Africa. This will enable the production of polio vaccines for more than 40 African countries.

Middle East & Africa Injectable Drug Delivery Device Manufacturers

BD is a global medical technology leader with a broad product offering that includes medical devices, instruments, systems, and reagents across 190+ countries. The company focuses on three core business segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical includes Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring. Its Pharmaceutical Systems unit supplies needles, syringes, and IV catheters. The Life Sciences segment includes Integrated Diagnostic Solutions and Biosciences. The Interventional segment encompasses surgery, peripheral intervention, and urology & critical care, focusing on minimally invasive and critical care devices. It has an international presence with subsidiary operations in the US, Canada, and Germany.

B. Braun SE is a medical and pharmaceutical technology company that develops, manufactures, and supplies various healthcare products to improve patient care and treatment outcomes worldwide. The company emphasizes continued growth and investment in modern healthcare technologies, with significant R&D spending to drive innovative solutions across its entire product portfolio, which includes medical devices integral to injectable drug administration. Its solutions aim to improve clinical workflows, enhance patient safety, and increase treatment efficiency by combining advanced products with software and services.

Middle East & Africa Injectable Drug Delivery Formulation Manufacturers

Sanofi is a global biopharmaceutical company that focuses on researching, developing, manufacturing, and marketing a large portfolio of prescription and vaccine products and therapies for various significant medical needs, including immunology, oncology, rare diseases, neurology, diabetes, cardiovascular disease, and infectious diseases. Its business operations are categorized into two main sectors: Pharmaceuticals and Vaccines. A strong pipeline and R&D efforts have been implemented and continue to support these two sectors, with a strong focus on biologics, immunotherapy, and next-generation platforms. As a constituent within the largest vaccine makers worldwide via Sanofi Vaccines, it supplies solutions for pediatric, travel, endemic, and seasonal immunizations.

Novartis AG is a global biopharmaceutical company with a focus on developing innovative medications, biologics, and high-value therapeutic approaches to address pressing global disease burdens. Novartis is committed to its strategy and focus on developing and innovating therapies based on its strong R&D investment and financial performance. Although Novartis primarily focuses on drug innovation rather than medical devices, its biologics and treatment therapies within injectable biologics play an essential role in patient treatment and addressing various disease areas, including cancer, immunological disorders, and rare diseases.

Market Ranking (Device Manufacturers)

The top injectable drug delivery device companies in the Middle East & Africa are BD (US), B. Braun SE (Germany), Terumo Corporation (Japan), Baxter (US), and Cardinal Health (US). BD is strengthening its position in the space of injectable drug delivery with high-quality collections of prefillable syringes, safety-engineered injection devices, as well as advanced platforms that additionally accommodate biologics and high-viscosity formulations. B. Braun SE offers syringes, needles, and integrated delivery systems designed for hospital and acute-care settings. Terumo Corporation is also enhancing its drug delivery techniques with its precision-engineered syringes and injection devices, supported by polymer-based delivery systems optimized for biologics and specialty injectables. Baxter continues to lead in the injectable delivery footprint, deploying strong device platforms for hospital, critical care, and medication administration workflows. These have already been significantly reinforced by its long-established infusion and drug delivery systems. Cardinal Health is focusing on all-inclusive medication delivery products, including safety syringes, sterile packaging, and supply chain solutions that support the intensive distribution and clinical utilization of injectable therapies.

Market Ranking (Formulation Manufacturers)

The top injectable drug delivery formulation companies in the Middle East & Africa are Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (US), GSK plc (UK), and Hikma Pharmaceuticals PLC (UK). The presence of Sanofi in injectable therapies will be strengthened with its diversified portfolio of biologics and vaccines. Novartis AG will further develop its injectable product offerings with its new biologics for immunology, oncology, and rare diseases. Its expertise and production facilities will be used for biologics requiring special production facilities. The injectable business of Pfizer Inc. will be strengthened with its diversified product portfolio. Its global and diversified production capabilities will be backed for large-scale production. The presence and expertise of GSK will be strengthened with its product portfolio of vaccines and injectable therapies for immunology. Hikma Pharmaceuticals PLC will strengthen its presence with its diversified product offering for injectable therapies. Its product offerings include critical care, oncology, and anti-infective therapies.

Related Reports:

Middle East & Africa Injectable Drug Delivery Market by Product (Device, Needle-free injectors, Formulation, Solutions), Formulation Packaging (Vials, Cartridges), Therapeutic Application (Diabetes, Psoriasis), Site of Administration – Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com